Domov › Crohnova choroba › North Carolina
Klinické štúdie Crohnova choroba v štáte North Carolina
20 štúdií pre Crohnova choroba hľadá účastníkov v zariadeniach v štáte North Carolina.
Mestá v štáte North Carolina
Oficiálny text štúdie (anglicky)
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Digestive Health Partners /ID# 280490, Asheville
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 5. 10. 2026 · NCT07697456A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
- University of North Carolina at Chapel Hill, Chapel Hill
Prebieha náborFáza 4
Vek 18 a viac · Ženy · Aktualizované 5. 10. 2026 · NCT07654751A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of North Carolina Medical Center ( Site 5034), Chapel Hill
- Atrium Health Gastroenterology MMP ( Site 5105), Charlotte
Prebieha náborFáza 3
Vek 16 až 80 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06430801A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Charlotte Gastroenterology and Hepatology, P.L.L.C, Charlotte
- Carolina Digestive Diseases, Greenville
- Piedmont Healthcare, Statesville
- a 1 ďalších
Prebieha náborFáza 4
Vek 18 až 80 · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Digestive Health Partners - Biltmore Office /ID# 265539, Asheville
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina at Chapel Hill, Chapel Hill
- Charlotte Gastroenterology and Hepatology, PLLC, Charlotte
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina, Chapel Hill
- Atrium Health, Charlotte
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT07196722Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Coastal Research Institute - Fayetteville, Fayetteville
Prebieha náborFáza 3
Vek 18 až 70 · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
- OnSite Clinical Solutions-Site Number: 8400051, Charlotte
- Duke University Medical Center-Site Number: 8400093, Durham
- a 3 ďalších
Prebieha náborFáza 3
Vek 16 až 80 · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
- Cross Creek Medical Clinic-Site Number: 8400057, Fayetteville
Prebieha náborFáza 3
Vek 16 až 80 · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT07184944A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Cross Creek Medical Clinic, Fayetteville
- Peters Medical Research, High Point
- Wake Research Associates, Raleigh
Prebieha náborFáza 2
Vek 18 až 85 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06226883A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina Hospital, Chapel Hill
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 8. 2026 · NCT07577843Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of North Carolina, Chapel Hill
- Atrium Health Center for Gastroenterology and Surgery, Charlotte
- Wake Forest School of Medicine, Winston-Salem
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 8. 2026 · NCT07237516Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)
- University of North Carolina at Chapel Hill, Chapel Hill
Prebieha nábor
Vek 18 až 44 · Ženy · Aktualizované 14. 7. 2026 · NCT07337902Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Univ NC Chapel Hill /ID# 262198, Chapel Hill
Prebieha náborFáza 3
Vek 2 až 17 · Všetky pohlavia · Aktualizované 24. 6. 2026 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Levine Children's, Charlotte
Prebieha náborFáza 4
Vek 6 až 17 · Všetky pohlavia · Aktualizované 27. 5. 2026 · NCT05781152COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)
- University of North Carolina at Chapel Hill, Chapel Hill
- Atrium Health, Charlotte
- Duke Health System, Durham
Prebieha náborObservačná štúdia
Vek 1 až 18 · Všetky pohlavia · Aktualizované 17. 4. 2026 · NCT07198113A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400003, Chapel Hill
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 27. 3. 2026 · NCT06958536A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, High Point
- Mirador Therapeutics Selected Site, Raleigh
Prebieha náborFáza 2
Vek 18 až 80 · Všetky pohlavia · Aktualizované 12. 3. 2026 · NCT07113522Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- Evidera, a PPD Business Unit /ID# 238688, Morrisville
Prebieha náborObservačná štúdia
Všetky vekové kategórie · Ženy · Aktualizované 17. 7. 2025 · NCT04846959Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.